Add-on Acquisition • Life Science

Vernalis Acquires Pragma Pharmaceuticals

On October 2, 2015, Vernalis acquired life science company Pragma Pharmaceuticals

Acquisition Context

This is Vernalis’ 1st transaction in the Life Science sector.
This is Vernalis’ 1st transaction in the United States.
This is Vernalis’ 1st transaction in New York.

Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	October 2, 2015
Target	Pragma Pharmaceuticals
Sector	Life Science
Buyer(s)	Vernalis
Deal Type	Add-on Acquisition

Target Company

Pragma Pharmaceuticals

Locust Valley, New York, United States

Pragma Pharmaceuticals LLC is a pharmaceutical firm.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Vernalis

Winnersh, United Kingdom

Category	Company
Founded	1988
Sector	Life Science
Employees	115
Revenue	21M GBP (2017)

DESCRIPTION

Vernalis is a commercial stage pharmaceutical company with three marketed products; Tuzistra® XR in the US prescription cough cold market, Moxatag®, a once-a-day formulation of the antibiotic amoxicillin, also for the US prescription market, and frovatriptan an acute treatment for migraine. Vernalis was founded in 1988 and is based in Winnersh, United Kingdom.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: New York	1 of 1
Country: United States	1 of 1
Year: 2015	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - New York M&A - United States M&A - 2015 M&A